O'Byrne, K, Esteban, E, Lee, CL, Hegmane, A, Volovat, C, Lo Russo, G, Ziogas, D, Atmaca, A, Sebastian, M, Majem, M. A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. Future Oncology. 2025; 21(30)DOI:10.1080/14796694.2025.2597404. PMID:41383151. IF:2.600(Q3/6D).

Salazar, J, Arranz, MJ, Martin-Broto, J, Serra, M, Palmerini, E, Martínez-García, J, Juan-Ribelles, A, Andion, M, Martinez-Trufero, J, Gutiérrez, G, Echebarria-Barona, A, Vaz-Salgado, MA, Regueiro, A, Alvarez, R, Valverde, C, Luna, P, Blay, P, Sebio, A. VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol. Pharmaceuticals. 2025; 18(12)DOI:10.3390/ph18121855. PMID:41471344. IF:4.800(Q1/2D).

Tsuboi, M, Wakelee, H, Spicer, JD, Gao, S, Liberman, M, Kato, T, Chen, KN, Dooms, C, Majem, M, Martinengo, GL, Bylicki, O, Abreu, DR, Halmos, B, Jones, DR, Chaft, J, Reck, M, Jense, E, Keller, SM, Samkari, A, Garassino, MC. Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.10.607. PMID:. IF:65.400(Q1/1D).

Molina-Pérez, MA, Martínez-Recio, S, Barba, A, Portu, M, Sanz-Beltran, J, Majem, M. Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?. Translational Lung Cancer Research. 2025; 14(11)DOI:10.21037/tlcr-2025-866. PMID:41367561. IF:3.500(Q1/3D).